Evaluating the effect of tumor size and sidedness on prognosis in stage 2 colon cancer: a retrospective population study

被引:0
作者
Demir, H. [1 ]
Caglayan, D. [2 ]
Kaman, O. [3 ]
Inanc, M. [4 ]
Urvay, S. [5 ]
Beypinar, I [6 ]
Demirci, A. [7 ]
Davarci, S. E. [1 ]
Araz, M. [2 ]
Baykara, M. [1 ]
Artac, M. [2 ]
Yildiz, F. [3 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Dept Internal Med & Med Oncol, Sch Med, Afyon, Turkey
[2] Necmettin Erbakan Univ, Dept Internal Med & Med Oncol, Sch Med, Konya, Turkey
[3] Abdurrahman Yurtaslan Ankara Oncol Training & Res, Dept Internal Med & Med Oncol, Ankara, Turkey
[4] Erciyes Univ, Fac Med, Dept Internal Med & Med Oncol, Kayseri, Turkey
[5] Acibadem Univ, Dept Radiotherapy, Vocat Sch Hlth Serv, Istanbul, Turkey
[6] Eskisehir City Hosp, Dept Internal Med & Med Oncol, Eskisehir, Turkey
[7] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Sakarya, Turkey
关键词
Colon cancer; Tumor size; Tumor sidedness; Prognosis; ADJUVANT CHEMOTHERAPY; COLORECTAL-CANCER; SURVIVAL; SURVEILLANCE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: In this study. we aimed to evaluate the effect of tumor size and tumor sidedness on prognosis in patients with stage 2 colon cancer. PATIENTS AND METHODS: Data of 501 patients diagnosed with stage 2 colon cancer were evaluated retrospectively. It was evaluated whether the patients' age, gender, tumor differentiation, tumor node metastasis (TNM) stage, overall survival rate, and disease-free survival rate had any correlation with horizontal tumor diameter and tumor sidedness. In the ROC analysis performed to determine the cut-off value for the tumor diameter, which we think will predict survival, no significant results were obtained with maximum sensitivity and specificity. Therefore, the median value of the tumor diameter, which is 5 cm, was accepted as the cut-off value. Kaplan-Meier method and Cox regression analysis were used for survival analysis and determination of prognostic factors. RESULTS: When the patients were evaluated in terms of tumor localization, 189 (37.7%) patients had right colon tumors and 312 (62.3%) patients had left colon tumors. There was no statistically significant difference in terms of disease-free survival and overall survival according to tumor localization. When the patients were analyzed by dividing them into two groups according to the horizontal tumor size (<5 cm and >= 5 cm), no statistically significant difference was found between the groups in terms of disease-free survival (DFS) and overall survival (OS) p=0.085, p=0.699, respectively. CONCLUSIONS: Our results suggest that the management of patients with stage 2 colon cancer requires a better understanding of tumor biology rather than features such as tumor size and localization.
引用
收藏
页码:1328 / 1340
页数:13
相关论文
共 50 条
  • [31] A retrospective study based on SEER database: not all high-risk factors are equal for stage II colon cancer
    Li, Dong
    Jiang, Zongze
    Xian, Lili
    Yang, Chuanhua
    Long, Feiwu
    Liu, Wenneng
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (04) : 689 - 698
  • [32] Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study
    Babaei, Masoud
    Balavarca, Yesilda
    Jansen, Lina
    Lemmens, Valery
    van Erning, Felice N.
    van Eycken, Liesbet
    Vaes, Evelien
    Sjovall, Annika
    Glimelius, Bengt
    Ulrich, Cornelia M.
    Schrotz-King, Petra
    Brenner, Hermann
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (07) : 1480 - 1489
  • [33] Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension
    Zhang, Yang
    Sun, Yihua
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2016, 9 : 649 - 653
  • [34] Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study
    Zheng, C.
    Jiang, F.
    Lin, H.
    Li, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11) : 1524 - 1531
  • [35] Primary tumor sidedness is not prognostic factor in resectable colorectal cancer liver metastasis: a retrospective observational cohort study
    Jo, Sung Jun
    Kim, Jongman
    Shin, Jung Kyong
    Rhu, Jinsoo
    Huh, Jung Wook
    Choi, Gyu-seong
    Joh, Jae-Won
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2024, 107 (05) : 264 - 273
  • [36] Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study
    Weiwei Chen
    Hongmin Dong
    Gang Wang
    Juan Chen
    Wenling Wang
    World Journal of Surgical Oncology, 19
  • [37] Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study
    Chan, Joseph Chung Yan
    Diakos, Connie Irene
    Engel, Alexander
    Chan, David Lok Hang
    Pavlakis, Nick
    Gill, Anthony
    Clarke, Stephen John
    PLOS ONE, 2019, 14 (06):
  • [38] Prognostic value of tumor deposits and positive lymph node ratio in stage III colorectal cancer: a retrospective cohort study
    Liu, Lei
    Ji, Jie
    Ge, Xianxiu
    Ji, Zuhong
    Li, Jiacong
    Wu, Jie
    Zhu, Juntao
    Yao, Jianan
    Zhu, Fangyu
    Mao, Boneng
    Cao, Zhihong
    Zhou, Jinyi
    Miao, Lin
    Ji, Guozhong
    Hang, Dong
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (06) : 3470 - 3479
  • [39] Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study
    Stocker, Gertraud
    Hacker, Ulrich T.
    Fiteni, Frederic
    Mahachie, Jestinah John
    Roth, Arnaud D.
    Van Cutsem, Eric
    Peeters, Marc
    Lordick, Florian
    Mauer, Murielle
    EUROPEAN JOURNAL OF CANCER, 2018, 99 : 49 - 57
  • [40] Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study
    den Uil, Sjoerd H.
    van den Broek, Evert
    Coupe, Veerle M. H.
    Vellinga, Thomas T.
    Delis-van Diemen, Pien M.
    Bril, Herman
    Belt, Eric J. Th.
    Kranenburg, Onno
    Stockmann, Hein B. A. C.
    Belien, Jeroen A. M.
    Meijer, Gerrit A.
    Fijneman, Remond J. A.
    BMC GASTROENTEROLOGY, 2019, 19 (01)